In this strategy, an intermediate dose of an anti-VEGF receptor 2 (VEGFR2) antibody, DC101, was applied and successfully normalized tumor vessels to a certain extent such that oriented vascular structure was achieved with increased blood perfusion, decreased vascular density, and reduced necrotic and hypoxic regions [81]. Here, KDR is linked to neoplasm.